CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 54 enrolled
Drug / intervention
Iohexoldrug
Likely dose
Iohexol 5 mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01545531
NCT01545531N/ACompleted
CompareCT.gov

Two-Point Measurement of Glomerular Filtration Rate by Iohexol Plasma Disappearance

University of Washington·observational·Posted Mar 6, 2012·Updated Jan 4, 2017

In Brief

An observational study evaluating Iohexol for Renal Disease and Renal Insufficiency. Completed, enrolled 54 participants across 1 site.

Detailed Summary

The purpose of this study is to measure glomerular filtration rate (GFR) by iohexol plasma disappearance (gold standard) and measure serum Cystatin C levels (surrogate marker) in patients enrolled in our prospective study at baseline, day 100 and 1 year after hematopoietic cell transplant and determine if these levels correlate with serum creatinine and an estimated GFR using the Modification of Diet in Renal Disease (MDRD) equation and Schwartz formula in children.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Disease, Renal Insufficiency
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 6, 2012
Enrollment StartSep 1, 2008
Primary CompletionJan 1, 2016
TodayJul 2, 2026
Enrollment to primary: 7.3 yearsPosted 14.3 years ago

Interventions

Iohexoldrug

Iohexol, a non-ionic, low osmolar, X-ray contrast medium (OmnipaqueR) that is safe and non-toxic and used for angiographic and urographic procedures, is eliminated from plasma exclusively by glomerular filtration \[13\]. Study subject will receive 5 ml of iohexol solution (Omnipaque 300, corresponding to 647 mg iohexol per ml or 300 mg iodine per ml) through peripheral IV or central Line infusion over 1-2 minutes followed by 10 ml of saline solution at baseline, day 100 and 1 year after HCT.